Advances in genetic variation in metabolism-related fatty liver disease

Fan Shi; Mei Zhao; Shudan Zheng; Lihong Zheng; Haiqiang Wang

doi:10.3389/fgene.2023.1213916

Advances in genetic variation in metabolism-related fatty liver disease

Front Genet. 2023 Sep 11:14:1213916. doi: 10.3389/fgene.2023.1213916. eCollection 2023.

Authors

Fan Shi¹, Mei Zhao¹, Shudan Zheng¹, Lihong Zheng², Haiqiang Wang³

Affiliations

¹ School of Heilongjiang University of Chinese Medicine, Harbin, China.
² Department of Internal Medicine, Fourth Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, China.
³ Department of Internal Medicine, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, China.

Abstract

Metabolism-related fatty liver disease (MAFLD) is the most common form of chronic liver disease in the world. Its pathogenesis is influenced by both environmental and genetic factors. With the upgrading of gene screening methods and the development of human genome project, whole genome scanning has been widely used to screen genes related to MAFLD, and more and more genetic variation factors related to MAFLD susceptibility have been discovered. There are genetic variants that are highly correlated with the occurrence and development of MAFLD, and there are genetic variants that are protective of MAFLD. These genetic variants affect the development of MAFLD by influencing lipid metabolism and insulin resistance. Therefore, in-depth analysis of different mechanisms of genetic variation and targeting of specific genetic variation genes may provide a new idea for the early prediction and diagnosis of diseases and individualized precision therapy, which may be a promising strategy for the treatment of MAFLD.

Keywords: HSD17B13; MAFLD; PNPLA3; genetic variation; therapeutic potential.

Publication types

Review